Day Trading Reports
  • Business
  • World News
  • Politics
  • Investing
  • Business
  • World News
  • Politics
  • Investing

Day Trading Reports

Politics

Trump amends executive order raising China tariffs to 20% over ‘failure to address’ fentanyl crisis

by admin March 4, 2025
March 4, 2025
Trump amends executive order raising China tariffs to 20% over ‘failure to address’ fentanyl crisis

The White House announced Monday that China will face increased tariffs, citing the ongoing fentanyl crisis in the U.S. as the main reason for the decision.

In a post on X, the Rapid Response 47 account shared the text of an executive order (EO) signed by President Donald Trump on Monday. The Chinese government will now face 20% tariffs ‘over their failure to address the fentanyl pouring into our country,’ the EO stated.

The tariffs against China, which were originally only 10%, will go into effect on Tuesday. In Monday’s order, Trump said that the Chinese government has failed ‘to blunt the sustained influx of synthetic opioids, including fentanyl, flowing from [their country],’ and that such failure constitutes an ‘unusual and extraordinary threat.’

Trump also said that the crisis jeopardizes the ‘national security, foreign policy, and economy of the United States.’

‘I have determined that the [People’s Republic of China] has not taken adequate steps to alleviate the illicit drug crisis through cooperative enforcement actions, and that the crisis described in Executive Order 14195 has not abated,’ the order read. 

‘In recognition of the fact that the PRC has not taken adequate steps to alleviate the illicit drug crisis, section 2(a) of Executive Order 14195 is hereby amended by striking the words ‘10 percent’ and inserting in lieu thereof the words ‘20 percent’.’

The Trump administration is already imposing 25% tariffs on Canadian and Mexican goods, which were announced last month and will also go into effect on Tuesday. On Monday, Peter Navarro, the White House senior counselor on trade and manufacturing, defended the tariffs to CNBC and argued that the issue ‘starts in communist China with the precursor chemicals.’

‘It comes into Mexico, and they make the fentanyl. But they also have these pill presses. So they do the counterfeits,’ Navarro explained. ‘And they’re using Canada as a transit hub and secondary point to manufacture as well. So this is a Canada-Mexico-China thing.’

The Chinese government has opposed the tariffs since they were announced. In a Feb. 1 statement, China’s Ministry of Foreign Affairs claimed that China is ‘one of the world’s toughest countries on counternarcotics both in terms of policy and its implementation.’

‘Additional tariffs are not constructive and bound to affect and harm the counternarcotics cooperation between the two sides in the future,’ the statement read. ‘China calls on the U.S. to correct its wrongdoings, maintain the hard-won positive dynamics in the counternarcotics cooperation, and promote the steady, sound and sustainable development of China-U.S. relationship.’

Fox News Digital’s Anders Hagstrom contributed to this report.

This post appeared first on FOX NEWS

previous post
Theme of Trump’s address to Congress revealed
next post
Workers survive 36 hours buried under India avalanche

Related Posts

House votes to make Trump Gulf of America...

May 9, 2025

Trump announces US ambassador nominations that include mayor...

March 8, 2025

Biden’s former spokesman slams Trump and GOP for...

March 21, 2025

Democratic lawmaker demands Musk, OPM stop sending mass...

February 28, 2025

DOGE’s greatest hits: Look back at the department’s...

April 30, 2025

Tulsi Gabbard’s warning to Senate on Syria proves...

March 9, 2025

House Dem fumes over Musk’s DOGE crackdown during...

February 14, 2025

Trump eyes control of Ukraine’s nuclear plants as...

March 23, 2025

Iowa witness held in missing American student case...

March 19, 2025

Speaker Johnson moves on Senate’s Trump budget bill...

April 6, 2025

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Editors’ Picks

    • 1

      Forum Energy Metals and Global Uranium Announce Exploration Update on Drill Targeting, Northwest Athabasca Project, Saskatchewan

      January 31, 2025
    • 2

      Mega M&A: Rio Tinto-Glencore Merger Sparks Chatter

      January 28, 2025
    • 3

      Excellent 90% recoveries at Cork Tree Well & Board Update

      February 17, 2025
    • 4

      Financial Agreement signed releasing $2M grant

      January 23, 2025
    • 5

      Netflix shares soar as company reports surging revenue, tops 300 million subscribers

      January 23, 2025
    • 6

      Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

      January 23, 2025
    • 7

      FDA officially authorizes Zyn nicotine pouches for sale following health review

      January 23, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: daytradingreports.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 daytradingreports.com | All Rights Reserved